DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
Subscribe To Our Newsletter & Stay Updated
